Degu Insulin Liraglutide Injection should be administered subcutaneously and the exact dosage should be determined by a medical professional based on the patient’s blood glucose profile. The usual size of Degu Insulin Liraglutide is 3 mL each, containing 300 units of Degu Insulin and 10.8 mg of Liraglutide. Degu insulin liraglutide injection is a combination of two hypoglycemic agents, degu insulin and liraglutide. Among them, Degu insulin is a long-acting insulin; liraglutide is a glucagon-like peptide-1 receptor agonist, which mainly acts on pancreatic β-cells, promotes insulin synthesis and secretion, and has the effect of lowering blood glucose. Degu Insulin Liraglutide Injection is suitable for patients with type 2 diabetes mellitus with poor glycemic control, based on diet and exercise control, combined with other oral hypoglycemic drugs to control blood glucose. It is contraindicated in patients with type 1 diabetes mellitus and in patients with diabetic ketoacidosis. Common adverse reactions are hypoglycemia, diarrhea, nausea, headache, and hypokalemia. Administration is by subcutaneous injection once daily. Specific dosage should be consulted with a medical professional to formulate a treatment plan based on individual blood glucose situation. Seek medical advice if you feel unwell.